Rethinking the paradigm: Evaluation of ketamine as a neurosurgical anesthetic

AANA Journal

Volumn 80, Issue 6, 2012, Pages 445-452

  Bowles, Eric D ^a   Gold, Michele E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Ketamine; N methyl D aspartate; Neurodestruction; Neuroprotection; NMDA

Indexed keywords

CATECHOLAMINE; ETOMIDATE; FENTANYL; INTERLEUKIN 6; ISOFLURANE; KETAMINE; MIDAZOLAM; MORPHINE; MU OPIATE RECEPTOR; MUSCARINIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; PROPOFOL; SUFENTANIL; VOLTAGE GATED SODIUM CHANNEL;

ADRENERGIC STIMULATION; ANALGESIA; ANESTHESIST; ANTINOCICEPTION; ARTICLE; ASSISTED VENTILATION; BRONCHODILATATION; CLINICAL EVALUATION; DRUG BLOOD LEVEL; HEART SURGERY; HEMODYNAMICS; HUMAN; INTRACRANIAL PRESSURE; LOCAL ANESTHESIA; MONOAMINERGIC NERVE; NEUROPROTECTION; NEUROSURGERY; SURGICAL PATIENT;

ANESTHETICS, DISSOCIATIVE; CEREBROVASCULAR CIRCULATION; HUMANS; KETAMINE; NURSE ANESTHETISTS; SYMPATHETIC NERVOUS SYSTEM;

EID: 84871587184     PISSN: 00946354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Heron MP, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stats Rep. 2009;57(14):1-134.
2. Flynn RW, MacWalter RS, Doney AS. The cost of cerebral ischaemia. Neuropharmacology. 2008;55(3):250-256.
3. Langlois JA, Rutland-Brown W, Thomas KE. Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2006.
4. Urwin SC, Menon DK. Comparitive tolerability of sedative agents in head-injured adults. Drug Saf. 2004;27(2):107-133.
5. Koerner IP, Brambrink AM. Brain protection by anesthetic agents. Curr Opin Anaesthesiol. 2006;19:481-486.
6. Kuroda Y, Murakami M, Tsuruta J, Murakawa T, Sakabe T. Preservation of the ration of cerebral blood flow/metabolic rate for oxygen during prolonged anesthesia with isoflurane, sevoflurane, and halothane in humans. Anesthesiology. 1996;84(3):555-561.
7. Salt TE, Wilson DG, Prasad SK. Antagonism of N-methylaspartate and synaptic responses of neurons in the rat ventrobasal thalamus by ketamine and MK-801. Br J Pharmacol. 1988;94(2):443-448.
8. Durieux ME. Inhibition of ketamine of muscarinic acetylcholine receptor function. Anesth Analg. 1995;81(1):57-62.
9. Smith DJ, Bouchal RL, deSanctis CA, et al. Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro. Neuropharmacology. 1987;26(9):1253-1260.
10. Crisp T, Perrotti JM, Smith DL, Stafinsky JL, Smith DJ. The local monoaminergic dependency of spinal ketamine. Eur J Pharmacol. 1991;194 (2-3):167-172.
11. Benoit E, Carratú MR, Dubois JM, Mitolo-Chieppa D. Mechanism of action of ketamine in the current voltage clamped myelinated nerve fibre of the frog. Br J Pharmacol. 1986;87(2):291-297.
12. Baum VC, Tecson ME. Ketamine inhibits transsarcolemmal calcium entry in guinea pig myocardium: direct evidence by single cell voltage clamp. Anesth Analg. 1991;73(6):804-807.
13. Lundy PM, Lockwood PA, Thompson G, Frew R. Differential effects of ketamine isomers on neuronal and extraneuronal catecholamine uptake mechanisms. Anesthesiology. 1986;64(3):359-363.
14. Bartoc C, Frumento RJ, Jalbout M, Bennett-Guerrero E, Du E, Nishanian E. A randomized, double-blind, placebo-controlled study assessing the anti-inflammatory effects of ketamine in cardiac surgical patients. J Cardiothor Vasc Anesth. 2006;20(2):217-222.
15. Craven R. Ketamine. Anaesthesia. 2007;62(suppl 1):48-53.
16. Hirota K, Lambert DG. Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anaesth. 1996;77(4):441-444.
17. Kolenda H, Gremmelt A, Rading S, Braun U, Markakis E. Ketamine for analgosedative therapy in intensive care treatment of head-injured patients. Acta Neurochir. 1996;138:1193-1199.
18. Hudetz, JA, Pagel, PS. Neuroprotection by ketamine: A review of the experimental and clinical evidence. J Cardiothor Vasc Anesth. 2010; 24(1):131-142.
19. Bar-Joseph G, Guilburd Y, Tamir A, Guilburd JN. Effectiveness of ketamine in decreasing intracranial pressure in children with intracranial hypertension. J Neurosurg Pediatr. 2009;4(1):40-46.
20. Bourgoin A, Albanése J, Wereszczynski N, Charbit M, Vialet R, Martin C. Safety of sedation with ketamine in severe head injury patients: comparison with sufentanil. Crit Care Med. 2003;31(3):711-717.
21. Nagase K, Iida H, Ohata H, Dohi S. Ketamine, not propofol, attenuates cerebrovascular response to carbon dioxide in humans with isoflurane anesthesia. J Clin Anesth. 2001;13(8):551-555.
22. Sakai K, Cho S, Fukusaki M, Shibata O, Sumikawa K. The effects of propofol with and without ketamine on human cerebral blood flow velocity and CO2 response. Anesth Analg. 2000;90(2):377-382.
23. Hardingham GE. Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem Soc Trans. 2009;37(Pt 6):1147-1160.
24. Lafon-Cazal M, Perez V, Bockaert J, Marin P. Akt mediates the anti-apoptotic effect of NMDA but not that induced by potassium depolarization in cultured cerebellar granule cells. Eur J Neurosci. 2002;16(4):575-583.
25. Soriano FX, Papadia S, Hofmann F, Hardingham NR, Bading H, Hardingham GE. Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability. J Neurosci. 2006; 26(17):4509-4518.
26. Lau D, Bading H. Synaptic activity-mediated suppression of p53 and induction of nuclear calcium-regulated neuroprotective genes promote survival through inhibition of mitochondrial permeability transition. J Neurosci. 2009;29(14):4420-4429.
27. Al-Mubarak B, Soriano FX, Hardingham GE. Synaptic NMDAR activity suppresses FOXO1 expression via a cis-acting FOXO binding site: FOXO1 is a FOXO target gene. Channels (Austin). 2009;3(4):233-238.
28. Xu J, Kurup P, Zhang Y, et al. Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J Neurosci. 2009;29(29):9330-9343.
29. Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002;5(5):405-414.
30. Reeker W, Werner C, Möllenberg O, Mielke, L, Kochs, E. High-dose S(+)-ketamine improves neurological outcome following incomplete cerebral ischemia in rats. Can J Anaesth. 2000;47(6):572-578.
31. Himmelseher S, Durieux ME. Revising a dogma: ketamine for patients with neurological injury? Anesth Analg. 2005;101(2):524-534.
32. Liu Y, Zhang G, Gao C, Hou X. NMDA receptor activation results in tyrosine phosphorylation of NMDA receptor subunit 2A(NR2A) and interaction of Pyk2 and Src with NR2A after transient cerebral ischemia and reperfusion. Brain Res. 2001;909(1-2):51-58.
33. Lan JY, Skeberdis VA, Jover T, et al. Protein kinase C modulates NMDA receptor trafficking and gating. Nat Neurosci. 2001;4(4):382-390.
34. Choi DW. Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci Lett. 1985;58(3):293-297.
35. Garthwaite G, Garthwaite J. Neurotoxicity of excitatory amino acid receptor agonists in rat cerebellar slices: dependence on calcium concentration. Neurosci Lett. 1986;66(2):193-198.
36. Bano D, Young KW, Guerin CJ, et al. Cleavage of the plasma membrane Na+/Ca2+ exchanger in excitotoxicity. Cell. 2005;120(2):275-285.
37. Dugan LL, Sensi SL, Canzoniero LM, et al. Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. J Neurosci. 1995;15(10):6377-6388.
38. Ankarcrona M, Dypbukt JM, Bonfoco E, et al. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron. 1995;15(4):961-973.
39. Dick O, Bading H. Synaptic activity and nuclear calcium signaling protect hippocampal neurons from death signal-associated nuclear translocation of FoxO3a induced by extrasynaptic N-methyl-D-aspartate receptors. J Biol Chem. 2010;285(25):19354-19361.
40. Grathwohl KW, Black IH, Spinella PC, et al. Total intravenous anesthesia including ketamine versus volatile gas anesthesia for combat-related operative traumatic brain injury. Anesthesiology. 2008;109(1):44-53.
41. Holcomb HH, Lahti AC, Medoff DR, Weiler M, Tamminga CA. Sequential regional cerebral blood flow brain scans using PET with H2(15)O demonstrate ketamine actions in CNS dynamically. Neuropsychopharmacology. 2001;25(2):165-172.
42. Långsjö JW, Kaisti KK, Aalto S, et al. Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology. 2003;99(3):614-623.
43. Engelhard K, Werner C, Möllenburg O, Kochs E. S(+)-ketamine/propofol maintain dynamic cerebrovascular autoregulation in humans. Can J Anaesth. 2001;48(10):1034-1039.
44. Nagels W, Demeyere R, Van Hemelrijck J, Vandenbussche E, Gijbels K, Vandermeersch E. Evaluation of the neuroprotective effects of S(+)-ketamine during open-heart surgery. Anesth Analg. 2004;98(6):1595-1603.
45. Zilberstein G, Levy R, Rachinsky M, et al. Ketamine attenuates neutrophil activation after cardiopulmonary bypass. Anesth Analg. 2002;95(3):531-536.
46. Biffl WL, Moore EE, Moore FA, et al. Interleukin-6 delays neutrophil apoptosis. Arch Surg. 1996;131(1):24-29.
47. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular disease. Med Hypotheses. 2004;62(4):499-506.
48. Bisoendial RJ, Kastelein JJ, Levels JH, et al. Activation of inflammation and coagulation after infusion of c-reactive protein in humans. Circ Res. 2005;96(7):714-716.
49. Smith FJ, Bartel PR, Hugo JM, Becker PJ. Anesthetic technique (sufentanil versus ketamine plus midazolam) and quantitative electroencephalographic changes after cardiac surgery. J Cardiothorac Vasc Anesth. 2006;20(4):520-525.
50. Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signaling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010;11(10):682-696.